版本:
中国

公司新闻: 浙江华海药业股份有限公司 (600521.SS)

600521.SS ( 上海证券交易所 )

13.05CNY
14 Jun 2019
涨跌 (%)

¥-0.44 (-3.26%)
收盘
¥13.49
开盘
¥13.50
当日最高
¥13.58
当日最低
¥13.04
成交量
9,568,400
平均成交量
17,176,809
52 周最高
¥28.60
52 周最低
¥9.80

选择日期:

UPDATE 2-FDA approves generic valsartan amid drug shortage

March 12 The U.S. Food and Drug Administration said on Tuesday it had approved a new generic version of blood pressure medicine valsartan, as the agency looks to ease shortages triggered by several manufacturers recalling the drug over possible cancer risk. 全文

UPDATE 3-New cancer-causing toxin found in recalled blood pressure pills

March 1 U.S. health regulators said on Friday a third cancer-causing toxin was found in some blood pressure pills recalled by India's Hetero Labs Ltd a day earlier, adding to a global recall of commonly used drugs to treat hypertension. 全文

UPDATE 3-New cancer-causing toxin found in recalled blood pressure pills

March 1 U.S. health regulators said on Friday a third cancer-causing toxin was found in some blood pressure pills recalled by India's Hetero Labs Ltd a day earlier, adding to a global recall of commonly used drugs to treat hypertension. 全文

CORRECTED-UPDATE 1-New cancer-causing toxin found in recalled blood pressure pills

March 1 U.S. health regulators said on Friday a third cancer-causing toxin was found in some blood pressure pills recalled by India's Hetero Labs Ltd a day earlier, adding to a global recall of commonly-used drugs to treat hypertension. 全文

UPDATE 1-Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

TOKYO, Feb 8 The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday. 全文

More blood pressure drugs may have shortages after recalls -FDA

NEW YORK, Jan 25 Additional shortages of blood pressure drugs in the United States are possible following recent recalls related to traces of a probable carcinogen found in some versions a particular class of hypertension medicines, the U.S. Food and Drug Administration said on Friday. 全文

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US

Jan 2 A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration. 全文

选择另外日期:

公司公告